BAS00602705 is an E-cadherin inhibitor. BAS00602705 exerts its function by blocking the trans-interactions of E-cadherin molecules within junctional complexes, without permanently altering E-cadherin expression levels. BAS00602705 significantly impairs invadopodia formation in pancreatic cancer cells. BAS00602705 can be used for the study of anti-invasive therapeutic strategies in cancers characterized by dysregulated E-cadherin-mediated invadopodia activity, such as pancreatic ductal adenocarcinoma (PDAC) [1].
References:
[1]. Dobric A, et al. E-Cadherin Is a Structuring Component of Invadopodia in Pancreatic Cancer. J Cell Mol Med. 2025 May;29(9):e70608.
References:
[1]. Dobric A, et al. E-Cadherin Is a Structuring Component of Invadopodia in Pancreatic Cancer. J Cell Mol Med. 2025 May;29(9):e70608.